Clinical impact of MYC abnormalities in plasma cell myeloma

Manier, 2017, Genomic complexity of multiple myeloma and its clinical implications, Nat Rev Clin Oncol, 14, 100, 10.1038/nrclinonc.2016.122 Morgan, 2012, The genetic architecture of multiple myeloma, Nat Rev Cancer, 12, 335, 10.1038/nrc3257 Walker, 2015, APOBEC family mutational signatures are associated with poor progresis in translocations in multiple myeloma, Nat Commun, 6, 6997, 10.1038/ncomms7997 Fonesca, 2003, The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma, Blood, 102, 2562, 10.1182/blood-2003-02-0493 Munshi, 2011, Consensus recommendations for risk stratification in multiple myeloma: report of the international myeloma workshop consensus panel 2, Blood, 117, 4696, 10.1182/blood-2010-10-300970 Chang, 2010, 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in pateints with multiple myeloma, Bone Marrow Transpl, 45, 117, 10.1038/bmt.2009.107 Glitza, 2015, Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma, Leuk Lymphoma, 56, 602, 10.3109/10428194.2014.924116 Avet-Loiseau, 2001, Rearranements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors, Blood, 98, 3082, 10.1182/blood.V98.10.3082 Affer, 2014, Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma, Leukemia, 28, 1725, 10.1038/leu.2014.70 Walker, 2014, Translcoations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients, Blood Cancer J, 4, e191, 10.1038/bcj.2014.13 Chiecchio, 2009, Frequent upregulation of MYC in plasma cell leukemia, Genes Chromosomes Cancer, 48, 624, 10.1002/gcc.20670 Chang, 2011, Clinical and biological implication of MYC activation: a common diffeence between MGUS and newly diagnosed multiple myeloma, Leukemia, 25, 1026, 10.1038/leu.2011.53 Rahnenfuhrer, 2005, Estimating cancer survival and clnical outcome based on genetic tumor progression scores, Bioinformatics, 21, 2438, 10.1093/bioinformatics/bti312 Bogojeska, 2008, An R package for estimating evolutionary pathways and genetic proression scores, Bioinformatics, 24, 2391, 10.1093/bioinformatics/btn410 Ketter, 2007, Application of oncogenetic trees mixtures as a biostatistical model of the clonal cytogenetic evolution of meningiomas, Int J Cancer, 121, 1473, 10.1002/ijc.22855 Urbschat, 2011, Clonal cytogenetic proression within intratumorally heterogeneous meningiomas predicts tumor recurrence, Int J Oncol, 39, 1601 An International Sysem for Human Cytogenetic Nomenclature. Eds.McGowan-Joran J, Simons A, Schmid M, Karger, basel, 2016. Feinerer, 2008, Text mining infrastructure in R, Stat Softw, 25, 1 Ramazzotti, 2015, CAPRI: efficient inference of cancer progression models from cross-sectional data, Bioinformatics, 31, 3016, 10.1093/bioinformatics/btv296 De Sano, 2016, RANCO: an R package for the inference of cancer progression models from heterogeneous genomic data, Bioinformatics, 32, 1911, 10.1093/bioinformatics/btw035 Bolli, 2014, Heterogeneity of genomic evolution and mutational profiles in multiple myeloma, Nat Commun, 5, 2997, 10.1038/ncomms3997 Chung, 2007, Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling, Cancer Res, 67, 2982, 10.1158/0008-5472.CAN-06-4046 Pedersen, 2014, MYC translocaton partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations, Eur J Haematol, 92, 42, 10.1111/ejh.12212